Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma
Status:
Not yet recruiting
Trial end date:
2026-08-31
Target enrollment:
Participant gender:
Summary
- Clinical Indication : Advanced adrenal cortical carcinoma after platinum-based
chemotherapy
- Trial Type : Single arm, prospective trial
- Route of administration : Intravenous (pembrolizumab) and peroral (lenvatinib)
- Treatment Groups : Single arm
- Number of trial participants : 30